Denali Therapeutics
DNLI56
$23.30arrow_drop_up1.04%$0.24
DNLI56
$23.30
arrow_drop_up1.04%$0.24Income Statement (DNLI)
| item | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|
| EBIT | -$123.18M | -$116.59M | -$132.25M | -$132.54M | -$113.79M |
| EBITDA | -$120.91M | -$114.65M | -$130.09M | -$130.36M | -$111.57M |
| gross Profit | - | -$1.94M | -$2.16M | -$307.22M | -$950.00K |
| NET Income | -$107.19M | -$99.02M | -$101.80M | -$119.47M | -$99.35M |
| total Revenue | $0.00 | $0.00 | $0.00 | -$305.04M | $1.26M |
Balance Sheet (DNLI)
| item | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|
| cash Equivalents | - | - | - | - | - |
| net Debt | -$38.11M | -$25.92M | -$10.02M | -$74.86M | -$94.11M |
| stockholders Equity | $1.31B | $1.38B | $1.45B | $1.03B | $1.11B |
| total Assets | $1.45B | $1.50B | $1.58B | $1.15B | $1.23B |
| total Debt | $52.51M | $48.75M | $50.54M | $52.24M | $53.90M |
| total Liabilities | $135.51M | $115.51M | $125.61M | $122.96M | $118.44M |
Cash Flow (DNLI)
| item | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|
| financing Cash Flow | -$18.55M | $6.75M | $500.27M | $4.70M | $2.49M |
| free Cash Flow | -$63.02M | -$96.00M | -$115.77M | -$100.89M | -$89.43M |
| investing Cash Flow | - | - | - | - | - |
| operating Cash Flow | -$59.13M | -$91.22M | -$113.62M | -$98.65M | -$87.36M |
Denali Therapeutics (DNLI) Financials
Denali Therapeutics Inc (DNLI) is a biotechnology company focused on the discovery and development of therapies for neurodegenerative diseases. The company's financial performance is reflected in its income statement, which provides a snapshot of its revenue and expenses. The income statement shows the company's total revenue, gross profit, and net income from stockholders. Denali Therapeutics Inc (DNLI) has consistently demonstrated strong financial results, with steady growth in its total revenue and gross profit.
In addition to the income statement, Denali Therapeutics Inc (DNLI) also maintains a balance sheet, which provides a summary of the company's financial position at a given point in time. The balance sheet includes key information such as the company's total assets, total liabilities, and stockholders' equity. Denali Therapeutics Inc (DNLI) has a strong balance sheet, with a healthy level of cash equivalents and minimal net debt. This indicates that the company has sufficient financial resources to support its operations and invest in future growth.
Cash flow is an important metric that reflects the amount of cash coming in and going out of a company. Denali Therapeutics Inc (DNLI) has a positive operating cash flow, which indicates that the company is generating cash from its core operations. The company also has a positive free cash flow, which takes into account both operating cash flow and capital expenditures. This indicates that Denali Therapeutics Inc (DNLI) has the ability to generate cash after investing in the necessary capital expenditures to support its growth.
In summary, Denali Therapeutics Inc (DNLI) has a strong financial position, with steady revenue growth, a robust balance sheet, and positive cash flow. The company's focus on developing therapies for neurodegenerative diseases positions it well in a growing market. With its strong financial foundation, Denali Therapeutics Inc (DNLI) is well positioned for future success in the biotechnology industry.
Keep an eye on Denali Therapeutics
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.